boric acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3035 10043-35-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • boric acid
  • boracic acid
  • trihydroxyborane
  • orthoboric acid
  • boron oxide hydroxide
A weakly acidic hydrate of boric oxide with mild antiseptic, antifungal, and antiviral properties. The exact mechanism of action of boric acid is unknown; generally cytotoxic to all cells. It is used in the treatment of yeast infections and cold sores
  • Molecular weight: 61.83
  • Formula: BH3O3
  • CLOGP: -1.75
  • LIPINSKI: None
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 61
kinase-selectivity-class ACVR2B,ACVRL1,AXL,BMX,BRAF,CDK9,EPHB4,GRK2,IRAK3,MAP2K6,MAP3K14,MAPK7,PIK3CD,PIK3CG,PRKDC,SYK,TEK,TGFBR1,ZAP70 19
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gastrointestinal toxicity 391.68 45.48 87 3367 9380 90615613
Pulmonary toxicity 369.29 45.48 86 3368 11445 90613548
Neoplasm malignant 290.16 45.48 89 3365 33791 90591202
Joint injury 280.53 45.48 86 3368 32578 90592415
Hepatotoxicity 263.69 45.48 89 3365 45753 90579240
Joint stiffness 183.89 45.48 79 3375 77963 90547030
Therapy non-responder 166.97 45.48 88 3366 136616 90488377
Musculoskeletal pain 151.06 45.48 89 3365 171162 90453831
C-reactive protein abnormal 144.20 45.48 78 3376 127351 90497642
Musculoskeletal stiffness 108.95 45.48 90 3364 296442 90328551
Treatment failure 104.94 45.48 89 3365 303839 90321154
Therapeutic product effect incomplete 95.35 45.48 70 3384 193826 90431167
Infection 91.52 45.48 89 3365 362005 90262988
Pain in extremity 78.73 45.48 91 3363 450438 90174555
Joint swelling 70.62 45.48 91 3363 503209 90121784
Arthropathy 60.57 45.48 72 3382 366170 90258823
Condition aggravated 54.57 45.48 88 3366 595457 90029536
Drug hypersensitivity 50.12 45.48 74 3380 463535 90161458
Drug intolerance 46.30 45.48 70 3384 447521 90177472

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gastrointestinal toxicity 215.59 44.95 51 2705 11097 110575446
Pulmonary toxicity 192.04 44.95 51 2705 17695 110568848
Neoplasm malignant 162.94 44.95 53 2703 37090 110549453
Joint injury 151.15 44.95 51 2705 39943 110546600
Hepatotoxicity 135.25 44.95 53 2703 63347 110523196
Joint stiffness 118.49 44.95 49 2707 67194 110519349
Therapy non-responder 86.77 44.95 52 2704 157255 110429288
Musculoskeletal pain 81.98 44.95 53 2703 182970 110403573
C-reactive protein abnormal 69.22 44.95 42 2714 129653 110456890
Musculoskeletal stiffness 63.91 44.95 54 2702 279768 110306775
Treatment failure 62.28 44.95 53 2703 277181 110309362
Infection 51.99 44.95 54 2702 362146 110224397
Allergy to chemicals 47.81 44.95 12 2744 3313 110583230
Myocardial reperfusion injury 46.00 44.95 7 2749 138 110586405
Synovial fluid analysis 45.23 44.95 11 2745 2670 110583873

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S02AA03 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
MeSH PA D007306 Insecticides
MeSH PA D010575 Pesticides
CHEBI has role CHEBI:74783 astringent
CHEBI has role CHEBI:747338 plastic heat stabilizer

Related Drugs by ATC class:

S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartratecefmenoximechloramphenicolchlorhexidineciprofloxacinclioquinolfosfomycingentamicinhydrogen peroxidemiconazoleneomycin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Antiseptic preparation indication 261276004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.99 acidic
pKa2 8.8 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
R57ZHV85D4 UNII
4018204 VUID
N0000146538 NUI
D01089 KEGG_DRUG
4018204 VANDF
C0006020 UMLSCUI
CHEBI:33118 CHEBI
BO3 PDB_CHEM_ID
CHEMBL42403 ChEMBL_ID
7628 PUBCHEM_CID
DB11326 DRUGBANK_ID
C032688 MESH_SUPPLEMENTAL_RECORD_UI
1700 RXNORM
399929 MMSL
4294 MMSL
4907 MMSL
003185 NDDF
21611007 SNOMEDCT_US
346349006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sha-lem HUMAN OTC DRUG LABEL 5 59862-100 OINTMENT 0.95 g TOPICAL unapproved drug other 10 sections
GYNOX-SOFT HUMAN OTC DRUG LABEL 1 66854-003 EMULSION 7 mg TOPICAL unapproved drug other 8 sections
ICEKING Skin Expert Anti-onychomycosis Gel HUMAN OTC DRUG LABEL 2 72501-072 GEL 0.20 g CUTANEOUS Export only 7 sections
Precilyx Vaginal Probiotics Gel HUMAN OTC DRUG LABEL 4 76986-017 GEL 0.03 g VAGINAL OTC Monograph Drug 10 sections
Gembooxt Vaginal Probiotics Gel HUMAN OTC DRUG LABEL 4 76986-021 GEL 0.03 g VAGINAL OTC Monograph Drug 10 sections